跳至主要内容
临床试验/EUCTR2009-012140-16-DE
EUCTR2009-012140-16-DE进行中(未招募)1 期

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ 28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus - The CANVAS Trial: CANagliflozin CardioVascular Assessment Study

Janssen-Cilag International NV0 个研究点目标入组 4,500 人开始时间: 2009年10月15日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
4,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients must have a diagnosis of T2DM and a history of or a high risk for CV disease
  • Patients must have inadequate diabetes control (as defined by HbA1c greater than or equal to 7.0% to less than or equal to 10.5% at screening) and be either (1) not currently on diabetes drug therapy or (2) on therapy with any approved class of diabetes drugs
  • Full details are included within the CANVAS study protocol.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 3150
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 1350

排除标准

  • A history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
  • History of one or more severe hypoglycemic (ie, very low blood sugar) episode within 6 months before screening

研究者

相似试验

已完成
4 期
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus ('CANVAS-R')Diabetes mellitusdiabetes
NL-OMON45079Janssen-Cilag250
进行中(未招募)
1 期
A study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants with Type 2 Diabetes Mellitus
EUCTR2013-003050-25-GBJanssen-Cilag International NV5,812
进行中(未招募)
1 期
A study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants with Type 2 Diabetes Mellitus
EUCTR2013-003050-25-FRJanssen-Cilag International NV5,700
进行中(未招募)
1 期
A study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants with Type 2 Diabetes MellitusPatients with type 2 diabetes mellitus (T2DM) receiving standard of care but with inadequate glycemic control and at elevated risk of cardiovascular (CV) eventsMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861
EUCTR2013-003050-25-ITJanssen-Cilag International NV5,700
进行中(未招募)
1 期
A study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants with Type 2 Diabetes MellitusPatients with type 2 diabetes mellitus (T2DM) receiving standard of care but with inadequate glycemic control and at elevated risk of cardiovascular (CV) eventsMedDRA version: 18.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861
EUCTR2013-003050-25-NLJanssen-Cilag International NV5,700